Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro

European Journal of Haematology

Volumn 95, Issue 1, 2015, Pages 65-74

  Frassanito, Maria Antonia ^a   Ruggieri, Simona ^a   Desantis, Vanessa ^a   Di Marzo, Lucia ^a   Leone, Patrizia ^a   Racanelli, Vito ^a   Fumarulo, Ruggiero ^a   Dammacco, Franco ^a   Vacca, Angelo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Antigen presenting cells; Multiple myeloma; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 10; LENALIDOMIDE; SYNDECAN 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; CD3 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; SDC1 PROTEIN, HUMAN;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOLOGY; CANCER REGRESSION; CELL CONTACT; CELL EXPANSION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; PHAGOCYTOSIS; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR ESCAPE; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD3; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PLASMA CELLS; SIGNAL TRANSDUCTION; SYNDECAN-1; T-LYMPHOCYTES, REGULATORY;

EID: 84931567102     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12481     Document Type: Article

References (40)

1. Maggi E, Cosmi L, Liotta F, Romagnani P, Romagnani S, Annunziato F. Thymic regulatory T cells. Autoimmun Rev 2005;4:579-86.
2. Jiang S, Lechler RI, He X-S, Huang J-F. Regulatory T cells and transplantation tolerance. Hum Immunol 2006;67:765-76.
3. Wang HL, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007;19:217-23.
4. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-74.
5. + regulatory thymocytes. Blood 2003;102:4107-14.
6. Lynch RG, Graff JR, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 1972;69:1540-4.
7. Bergenbrant S, Österborg A, Holm G, Mellstedt H, Lefvert AK. Anti-idiotypic antibodies in patients with monoclonal gammopathies. Relation to tumor load. Br J Haematol 1991;78:66-70.
8. Raitakari M, Brown RD, Gibson J, Joshua DE. T cells in myeloma. Hematol Oncol 2003;21:33-42.
9. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003;198:1753-7.
10. Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002;100:230-7.
11. Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol 2001;125:190-7.
12. + regulatory T cells in patients with multiple myeloma. Blood 2006;107:3940-9.
13. Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, Svane IM. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010;72:540-7.
14. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
15. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-6.
16. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S. Immunologic self-tolerance by maintained CD25+CD4+ regulatory T cells constitutively expressing cytotoxic lymphocyte-associated antigen 4. J Exp Med 2000;192:303-9.
17. Tai X, Van Laethem F, Pobezinsky L, et al. Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood 2012;119:5155-63.
18. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011;11:852-63.
19. Joshua DE, Brown RD, Ho PJ, Gibson J. Regulatory T cells and multiple myeloma. Clin Lymphoma Myeloma 2008;8:283-6.
20. Atanackovic D, Cao Y, Luetkens T, et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 2008;93:423-30.
21. Braga WM, da Silva BR, de Carvalho AC, Maekawa YH, Bortoluzzo AB, Rizzatti EG, Atanackovic D, Colleoni GW. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunol Immunother 2014;63:1189-97.
22. Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft AJ, Owen RG, Selby PJ, Cook G. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009;144:686-95.
23. Muthu Raja KR, Kubiczkova L, Rihova L, Piskacek M, Vsianska P, Hezova R, Pour L, Hajek R. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS One 2012;7:e49446.
24. Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006;107:301-4.
25. Gupta R, Ganeshan P, Hakim M, Verma R, Sharma A, Kumar L. Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leuk Res 2011;35:874-8.
26. Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 2007;7:305-10.
27. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701-11.
28. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
29. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
30. Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-54.
31. Bonanno G, Mariotti A, Procoli A, et al. Indoleamine 2, 3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. J Transl Med 2012;10:247.
32. + T regulatory cells: role of tumor-derived TGF-β. J Immunol 2007;178:2883-92.
33. Brown R, Kabani K, Favaloro J, et al. CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis. Blood 2012;120:2055-63.
34. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 2010;108:111-65.
35. Ostad M, Andersson M, Gruber A, Sundblad A. Expansion of immunoglobulin autoreactive T-helper cells in multiple myeloma. Blood 2008;111:2725-32.
36. Yi Q, Dabadghao s, Osterborg A, Bergenbrant S, Hol G. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. Blood 1997;90:1960-7.
37. Bergsagel PL, Smith AM, Szczepek A, Mant MJ, Belch AR, Pilarski LM. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995;85:436-47.
38. Yurin VL, Rudensky AY, Mazel SM, Blechman JM. Immunoglobulin-specific T-B cell interaction. II. T cell clones recognize the processed form of B cells' own surface immunoglobulin in the context of the major histocompatibility complex class II molecule. Eur J Immunol 1989;19:1685-91.
39. Racanelli V, Leone P, Frassanito MA, Brunetti C, Perosa F, Ferrone S, Dammacco F. Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood 2010;115:1185-93.
40. Feyler S, Scott GB, Parrish C, Jarmin S, Evans P, Short M, McKinley K, Selby PJ, Cook G. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012;7:e35981.